Own stem cells infused in spinal cord injury hope
NCT ID NCT03925649
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This expanded access program gives one patient with a spinal cord injury at the C5-C7 level a single infusion of their own stem cells (HB-adMSCs). The stem cells are taken from the patient's fat tissue and grown in a lab before being given back. The goal is to see if this approach is safe and might help with recovery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- autologous adipose-derived mesenchymal stem cells (HB-adMSCs)
- What this could lead to
- If this works, it could point toward a way to improve function or slow damage after spinal cord injury.
- What could go wrong
- This is an expanded access program for just one patient, not a full trial. It is too early to know if stem cells help spinal cord injury, and there may be risks like infection or immune reactions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SPINAL CORD INJURY AT C5-C7 LEVEL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Memorial Hermann Hospital-Clinical Research Unit (MMH-CRU)
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.